U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Mucosal Melanoma

MedGen UID:
1711109
•Concept ID:
C5237249
•
Neoplastic Process

Definition

Mucosal melanoma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Mucosal Melanoma

Professional guidelines

PubMed

Epidemiology, staging and management of mucosal melanoma of the head and neck: a narrative review.
Jeong YJ, Thompson JF, Ch'ng S
Chin Clin Oncol 2023 Jun;12(3):28. doi: 10.21037/cco-23-16. PMID: 37417292
Radiation treatment for adult rare cancers: Oldest and newest indication.
Fiorentino A, Gregucci F, Desideri I, Fiore M, Marino L, Errico A, Di Rito A, Borghetti P, Franco P, Greto D, Donato V
Crit Rev Oncol Hematol 2021 Mar;159:103228. Epub 2021 Jan 27 doi: 10.1016/j.critrevonc.2021.103228. PMID: 33508447
Systemic Therapy for Melanoma: ASCO Guideline.
Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P
J Clin Oncol 2020 Nov 20;38(33):3947-3970. Epub 2020 Mar 31 doi: 10.1200/JCO.20.00198. PMID: 32228358

Recent clinical studies

Etiology

Epidemiology, staging and management of mucosal melanoma of the head and neck: a narrative review.
Jeong YJ, Thompson JF, Ch'ng S
Chin Clin Oncol 2023 Jun;12(3):28. doi: 10.21037/cco-23-16. PMID: 37417292
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbé C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci PF, Dalle S, Khattak MA, Grob JJ, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto PA, Maio M
J Clin Oncol 2023 Aug 10;41(23):3917-3929. Epub 2023 Jun 12 doi: 10.1200/JCO.22.02199. PMID: 37307514
BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma.
Bai X, Mao LL, Chi ZH, Sheng XN, Cui CL, Kong Y, Dai J, Wang X, Li SM, Tang BX, Lian B, Zhou L, Yan XQ, Guo J, Si L
Neoplasma 2017;64(4):626-632. doi: 10.4149/neo_2017_419. PMID: 28485171
Update on primary head and neck mucosal melanoma.
López F, Rodrigo JP, Cardesa A, Triantafyllou A, Devaney KO, Mendenhall WM, Haigentz M Jr, Strojan P, Pellitteri PK, Bradford CR, Shaha AR, Hunt JL, de Bree R, Takes RP, Rinaldo A, Ferlito A
Head Neck 2016 Jan;38(1):147-55. Epub 2015 May 22 doi: 10.1002/hed.23872. PMID: 25242350Free PMC Article
Single-fraction stereotactic body radiation therapy for sinonasal malignant melanoma.
Bourgeois DJ 3rd, Singh AK
Head Neck 2015 Mar;37(3):E34-7. Epub 2014 Jul 21 doi: 10.1002/hed.23788. PMID: 24891086

Diagnosis

Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression.
Mitra D, Farr M, Nagarajan P, Ho J, Bishop AJ, Jhingran A, Farooqi AS, Frumovitz M, Amaria RN, McQuade JL, Jazaeri AA, Guadagnolo BA
Gynecol Oncol 2022 Dec;167(3):483-489. Epub 2022 Oct 11 doi: 10.1016/j.ygyno.2022.09.026. PMID: 36229264
Remission of Mucosal Melanoma of the Middle Ear and Petrous Temporal Bone and Reversal of Cranial Nerve Paresis Following Radiation and Single Agent Nivolumab: Clinical Capsule and Review of the Literature.
Carlson KJ, Volsky PG
Otol Neurotol 2021 Dec 1;42(10):e1560-e1564. doi: 10.1097/MAO.0000000000003293. PMID: 34282102
CDK4 and TERT amplification in head and neck mucosal melanoma.
Lyu J, Miao Y, Yu F, Chang C, Guo W, Zhu H
J Oral Pathol Med 2021 Nov;50(10):971-978. Epub 2021 Apr 12 doi: 10.1111/jop.13180. PMID: 33797827
Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma.
Nomura M, Oze I, Masuishi T, Yokota T, Satake H, Iwasawa S, Kato K, Andoh M
Int J Clin Oncol 2020 May;25(5):972-977. Epub 2020 Jan 14 doi: 10.1007/s10147-020-01618-9. PMID: 31938955
Update on primary head and neck mucosal melanoma.
López F, Rodrigo JP, Cardesa A, Triantafyllou A, Devaney KO, Mendenhall WM, Haigentz M Jr, Strojan P, Pellitteri PK, Bradford CR, Shaha AR, Hunt JL, de Bree R, Takes RP, Rinaldo A, Ferlito A
Head Neck 2016 Jan;38(1):147-55. Epub 2015 May 22 doi: 10.1002/hed.23872. PMID: 25242350Free PMC Article

Therapy

Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma.
Palamaris K, Moutafi M, Gakiopoulou H, Theocharis S
Int J Mol Sci 2022 Mar 27;23(7) doi: 10.3390/ijms23073660. PMID: 35409020Free PMC Article
New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.
Peil J, Bock F, Kiefer F, Schmidt R, Heindl LM, Cursiefen C, Schlereth SL
Int J Mol Sci 2022 Jan 27;23(3) doi: 10.3390/ijms23031478. PMID: 35163401Free PMC Article
Systemic Therapy for Melanoma: ASCO Guideline.
Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P
J Clin Oncol 2020 Nov 20;38(33):3947-3970. Epub 2020 Mar 31 doi: 10.1200/JCO.20.00198. PMID: 32228358
KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.
Meng D, Carvajal RD
Am J Clin Dermatol 2019 Jun;20(3):315-323. doi: 10.1007/s40257-018-0414-1. PMID: 30707374
BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma.
Bai X, Mao LL, Chi ZH, Sheng XN, Cui CL, Kong Y, Dai J, Wang X, Li SM, Tang BX, Lian B, Zhou L, Yan XQ, Guo J, Si L
Neoplasma 2017;64(4):626-632. doi: 10.4149/neo_2017_419. PMID: 28485171

Prognosis

Epidemiology, staging and management of mucosal melanoma of the head and neck: a narrative review.
Jeong YJ, Thompson JF, Ch'ng S
Chin Clin Oncol 2023 Jun;12(3):28. doi: 10.21037/cco-23-16. PMID: 37417292
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbé C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci PF, Dalle S, Khattak MA, Grob JJ, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto PA, Maio M
J Clin Oncol 2023 Aug 10;41(23):3917-3929. Epub 2023 Jun 12 doi: 10.1200/JCO.22.02199. PMID: 37307514
Update on primary head and neck mucosal melanoma.
López F, Rodrigo JP, Cardesa A, Triantafyllou A, Devaney KO, Mendenhall WM, Haigentz M Jr, Strojan P, Pellitteri PK, Bradford CR, Shaha AR, Hunt JL, de Bree R, Takes RP, Rinaldo A, Ferlito A
Head Neck 2016 Jan;38(1):147-55. Epub 2015 May 22 doi: 10.1002/hed.23872. PMID: 25242350Free PMC Article
Single-fraction stereotactic body radiation therapy for sinonasal malignant melanoma.
Bourgeois DJ 3rd, Singh AK
Head Neck 2015 Mar;37(3):E34-7. Epub 2014 Jul 21 doi: 10.1002/hed.23788. PMID: 24891086
Head and neck mucosal melanoma.
Mendenhall WM, Amdur RJ, Hinerman RW, Werning JW, Villaret DB, Mendenhall NP
Am J Clin Oncol 2005 Dec;28(6):626-30. doi: 10.1097/01.coc.0000170805.14058.d3. PMID: 16317276

Clinical prediction guides

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbé C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci PF, Dalle S, Khattak MA, Grob JJ, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto PA, Maio M
J Clin Oncol 2023 Aug 10;41(23):3917-3929. Epub 2023 Jun 12 doi: 10.1200/JCO.22.02199. PMID: 37307514
Real-world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: An all-case postmarketing surveillance in Japan.
Yamazaki N, Shimizu A, Ozaki M, Hamada M, Takeuchi N, Ito Y, Maekawa S
J Dermatol 2022 Nov;49(11):1096-1105. Epub 2022 Jul 27 doi: 10.1111/1346-8138.16518. PMID: 35896505Free PMC Article
OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study.
Cui C, Wang X, Lian B, Ji Q, Zhou L, Chi Z, Si L, Sheng X, Kong Y, Yu J, Li S, Mao L, Tang B, Dai J, Yan X, Bai X, Andtbacka R, Guo J
J Immunother Cancer 2022 Apr;10(4) doi: 10.1136/jitc-2021-004307. PMID: 35383116Free PMC Article
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y, Namikawa K, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Fujimoto N, Kuwatsuka Y, Onishi M, Kaneko T, Onuma T, Umeda Y, Ogata D, Takahashi A, Otsuka M, Teramoto Y, Yamazaki N
ESMO Open 2021 Dec;6(6):100325. Epub 2021 Nov 25 doi: 10.1016/j.esmoop.2021.100325. PMID: 34839104Free PMC Article
Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance.
Yamazaki N, Kiyohara Y, Uhara H, Tsuchida T, Maruyama K, Shakunaga N, Itakura E, Komoto A
J Dermatol 2020 Aug;47(8):834-848. Epub 2020 Jun 8 doi: 10.1111/1346-8138.15388. PMID: 32515086Free PMC Article

Recent systematic reviews

c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
Steeb T, Wessely A, Petzold A, Kohl C, Erdmann M, Berking C, Heppt MV
Eur J Cancer 2021 Nov;157:348-357. Epub 2021 Sep 22 doi: 10.1016/j.ejca.2021.08.015. PMID: 34562816
Systemic Therapy for Melanoma: ASCO Guideline.
Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P
J Clin Oncol 2020 Nov 20;38(33):3947-3970. Epub 2020 Mar 31 doi: 10.1200/JCO.20.00198. PMID: 32228358

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...